Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden-Reference-Cited by-同舟云学术

Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden

Published:2020-12-10 Issue:1 Volume:55 Page:1-8
ISSN:2168-1805
Container-title:Scandinavian Journal of Urology
language:en
Short-container-title:Scandinavian Journal of Urology

Author:

Svensson Johanna¹,Lissbrant Ingela Franck²^ORCID,Gauffin Oskar³,Hjälm-Eriksson Marie⁴,Kilany Suzanne¹,Fagerlund Karin¹,Stattin Pär³^ORCID

Affiliation:

1. Astellas Pharma a/s – Nordic Operations, Kastrup, Denmark

2. Department of Oncology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden

3. Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden

4. Department of Oncology and Pathology, Capio St. Göran’s Hospital, Karolinska Institute, Stockholm, Sweden

Funder

Astellas Pharma a/s – Nordic Operations, part of Astellas Pharma Inc., and Pfizer Inc.

Publisher

Informa UK Limited

Subject

Urology,Nephrology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21681805.2020.1851762

Reference24 articles.

1. NORDCAN. Cancer stat fact sheets; Nordic countries – Prostate; 2019 [cited 2019 Dec 16]. Available from: http://www-dep.iarc.fr/NORDCAN/english/StatsFact.asp?cancer=261&country=0.

2. null

3. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study

4. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

5. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States;Journal of Managed Care & Specialty Pharmacy;2024-07

2. Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy;International Journal of Technology Assessment in Health Care;2023

3. Impacto económico del tratamiento del cáncer de próstata metastásico y no metastásico en España;Economía de la Salud;2022-12

4. Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data;European Urology Open Science;2022-10

5. Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma;Disease Markers;2022-08-17